The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Open accessAbstract
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. Vaccination scale-up occurred as Qatar was undergoing its second and third waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which were triggered by expansion of the B.1.1.7 variant (starting in mid-January 2021) and the B.1.351 variant (starting in mid-February 2021). The B.1.1.7 wave peaked during the first week of March, and the rapid expansion of B.1.351 started in mid-March and continues to the present day. Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The test-negative design, which does not assume that a lack of a positive test equals a negative test and somewhat adjusts for testing volume, attempts to better mitigate this bias and is the reason we chose this method for this analysis”
From Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine (2022) · cites this paper as [25]
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [99]
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“Effectiveness was assessed with the use of an observational, test-negative, case–control design rather than a design in which cohorts of individual persons were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative design.14,15,31”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [38]
In the citing paper
“As compared with recent findings from Qatar on the effectiveness of the BNT162b2 vaccine against the alpha and beta variants,17 our findings suggest that effectiveness against the delta variant after a full vaccination course lies somewhere between these two.”
From Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) · cites this paper as [17]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“Likewise, clinical studies have reported somewhat reduced efficacy and effectiveness against the B.1.1.7, B.1.351, and B.1.617.2 variants (10–12).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [10]
In the citing paper
“The effectiveness of the BNT162b2 vaccine against the Beta variant was measured shortly after the population of Qatar had been vaccinated, whereas the effectiveness of BNT162b2 against the Delta variant was conducted several months after the second dose, which could be one of the reasons for low effectiveness of BNT162b2 against the Delta variant.404,405”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [405]
In the citing paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [19]
In the citing paper
“Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 879
Teerawattananon, Y., Anothaisintawee, T., Pheerapanyawaranun, C., Botwright, S., Akksilp, K., Sirichumroonwit, N., Budtarad, N., & Isaranuwatchai, W. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261930 · Cited by 50
Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters
Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J., & Enquist, L. W. (2021) · Journal of Virology · doi:10.1128/jvi.01973-21 · Cited by 52
Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study
Shoukat, A., VILCHES, T. N., Moghadas, S. M., Sah, P., Schneider, E. C., Shaff, J., Zucker, J. R., Quinn, C., Chokshi, D. A., & Galvani, A. P. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100085 · Cited by 51
Bošnjak, B., Odak, I., Barros‐Martins, J., Sandrock, I., Hammerschmidt, S. I., Permanyer, M., Patzer, G. E., Georgiev, H., Jauregui, R. G., Tscherne, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772240 · Cited by 50
An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
Pascual‐Iglesias, A., Cantón, J., Ortega‐Prieto, A. M., Jiménez-Guardeño, J. M., & Regla-Nava, J. Á. (2021) · Pathogens · doi:10.3390/pathogens10081030 · Cited by 50
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 49
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
SARS-CoV-2 variants: biology, pathogenicity, immunity and control
Uraki, R., Korber, B., Diamond, M., & Kawaoka, Y. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01255-x · Cited by 50
Yang, W., & Shaman, J. L. (2021) · Nature Communications · doi:10.1038/s41467-021-25913-9 · Cited by 48
Ayoub, H. H., Mumtaz, G. R., Seedat, S., Makhoul, M., Chemaitelly, H. S., & Abu-Raddad, L. J. (2021) · Global Epidemiology · doi:10.1016/j.gloepi.2021.100068 · Cited by 48
Self-citationVeneti, L., Seppälä, E. M., Storm, M. L., Salamanca, B. V., Buanes, E. A., Aasand, N., Naseer, U., Bragstad, K., Hungnes, O., Bøås, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258513 · Cited by 46
Butt, A. A., Talisa, V. B., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac328 · Cited by 48
Self-citationBonifazi, G., Breve, B., Cirillo, S., Corradini, E., & Virgili, L. (2022) · Information Processing & Management · doi:10.1016/j.ipm.2022.103095 · Cited by 46
Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and ReportsPreprint
Shapiro, J., Dean, N. E., Madewell, Z. J., Yang, Y., Halloran, M. E., & Longini, I. M. (2021) · medRxiv · doi:10.1101/2021.05.20.21257461 · Cited by 46
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj0847 · Cited by 45
Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 51
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Mlčochová, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T. A., Ferreira, I., Datir, R. P., et al. (2021) · Greater South Information System · doi:10.60692/dy28a-h7650 · Cited by 44
Vignier, N., Bérot, V., Bonnave, N., Peugny, S., Ballet, M., Jacoud, E., Michaud, C., Gaillet, M., Djossou, F., Blanchet, D., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211427 · Cited by 44
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Tayar, E., Abdeen, S., Alah, M. A., Chemaitelly, H. S., Bougmiza, I. M., Ayoub, H. H., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Al‐Romaihi, H. E., et al. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.016 · Cited by 44
Self-citationTesting Fractional doses of COVID-19 Vaccines
Więcek, W., Ahuja, A., Chaudhuri, E., Kremer, M. R., Gomes, A. S., Snyder, C. M., Tabarrok, A. T., & Tan, B. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116932119 · Cited by 43
Rzymski, P., Pazgan−Simon, M., Simon, K. A., Łapiński, T. W., Zarębska‐Michaluk, D., Szczepańska, B., Chojnicki, M., Mozer‐Lisewska, I., & Flisiak, R. (2021) · Vaccines · doi:10.3390/vaccines9070781 · Cited by 42
SARS-CoV-2 Vaccines: Where Are We Now?
Flanagan, K. L., MacIntyre, C. R., McIntyre, P. B., & Nelson, M. R. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.07.016 · Cited by 44
Chen, Z., Zhang, Y., Wang, M., Islam, M. S., Liao, P., Hu, Y., & Chen, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73583 · Cited by 42
Klemis, V., Schmidt, T., Schub, D., Mihm, J., Marx, S., Abu‐Omar, A., Ziegler, L., Hielscher, F., Guckelmus, C., Urschel, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32321-0 · Cited by 45
Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
Mancuso, M., Eikenberry, S. E., & Gumel, A. B. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.08.008 · Cited by 42
Evolution of the SARS-CoV-2 genome and emergence of variants of concern
Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 41
Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity
Zhou, W., Xu, C., Wang, P., Anashkina, A. A., & Jiang, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab375 · Cited by 42
Trimpert, J., Adler, J. M., Eschke, K., Abdelgawad, A., Firsching, T. C., Ebert, N., Thao, T. T. N., Gruber, A. D., Thiel, V., Osterrieder, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abk0172 · Cited by 41
Orkin, M. (1993) · PubMed · Cited by 41
Ayoub, H. H., Tomy, M., Chemaitelly, H. S., Altarawneh, H. N., Coyle, P. V., Tang, P., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad239 · Cited by 40
Self-citationCOVID-19 vaccines: Immune correlates and clinical outcomes
Mahrokhian, S. H., Tostanoski, L. H., Vidal, S. J., & Barouch, D. H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2324549 · Cited by 43
County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States
McLaughlin, J. M., Khan, F. L., Pugh, S. J., Swerdlow, D. L., & Jódar, L. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100191 · Cited by 46
Pavot, V., Berry, C., Kishko, M., Anosova, N. G., Huang, D., Tibbitts, T., Raillard, A., Gautheron, S., Gutzeit, C., Koutsoukos, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29219-2 · Cited by 40
Bertollini, R., Chemaitelly, H. S., Yassine, H. M., Al‐Thani, M. H., Al‐Khal, A., & Abu-Raddad, L. J. (2021) · JAMA · doi:10.1001/jama.2021.9970 · Cited by 39
Self-citationLv, J., Wu, H., Xu, J., & Liu, J. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00977-x · Cited by 40
Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · doi:10.1101/2021.07.29.454333 · Cited by 275
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 42
Triveri, A., Serapian, S. A., Marchetti, F., Doria, F., Pavoni, S., Cinquini, F., Moroni, E., Rasola, A., Frigerio, F., & Colombo, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00857 · Cited by 38
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 39
Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37
Anderson, R. M., Vegvari, C., Hollingsworth, T. D., Pi, L., Maddren, R., Ng, C. W., & Baggaley, R. F. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0008 · Cited by 38
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 38
Zhao, W., Chen, W., Li, J., Chen, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2022) · mBio · doi:10.1128/mbio.00181-22 · Cited by 37
Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations
Schaefer, G. O., Leland, R. J., & Emanuel, E. (2021) · JAMA · doi:10.1001/jama.2021.13226 · Cited by 36
Chen, R. E., Gorman, M. J., Zhu, D. Y., Carreño, J. M., Yuan, D., VanBlargan, L. A., Burdess, S., Lauffenburger, D. A., Kim, W., Turner, J. S., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.004 · Cited by 37
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 36
Decreased memory B cell frequencies in COVID‐19 delta variant vaccine breakthrough infection
Tay, M. Z., Rouers, A., Fong, S., Goh, Y. S., Chan, Y., Chang, Z. W., Xu, W., Tan, C. W., Chia, W. N., Torres‐Ruesta, A., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115227 · Cited by 36
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 35
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 37
Khairullin, B. M., Zakarya, K. D., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M., Sarsenbayeva, G., Sultankulova, K. T., Chervyakova, O. V., Myrzakhmetova, B. S., Куралбаевич, Н. А., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101526 · Cited by 36
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 37
The variants of SARS‐CoV‐2 and the challenges of vaccines
Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 37
Tran, T. N.-A., Wikle, N. B., Albert, E., Inam, H., Strong, E. R., Břinda, K., Leighow, S. M., Yang, F., Hossain, S., Pritchard, J. R., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02038-w · Cited by 35
A COVID-19 vaccination model for Aotearoa New Zealand
Steyn, N., Plank, M. J., Binny, R. N., Hendy, S. C., Lustig, A. G., & Ridings, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-06707-5 · Cited by 35
Schmidt, P., Narayan, K. M., Li, Y., Kaku, C. I., Brown, M. E., Champney, E. R., Geoghegan, J. C., Vásquez, M., Krauland, E. M., Yockachonis, T. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2783 · Cited by 35
Adam, K. M. (2021) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-021-00147-1 · Cited by 34
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 34
Knabl, L., Lee, H., Wieser, M., Mur, A., Zabernigg, A. F., Knabl, L., Rauch, S., Böck, M., Schumacher, J., Kaiser, N., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00083-x · Cited by 35
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 36
COVID-19: Epidemiologie und Mutationen
Hemmer, C. J., Löbermann, M., & Reisinger, E. C. (2021) · Der Radiologe · doi:10.1007/s00117-021-00909-0 · Cited by 33
The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants
Yadegari, I., Omidi, M., & Smith?, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-00083-2 · Cited by 29
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 34
Wang, K., Wang, L., Li, M., Xie, B., He, L., Wang, M., Zhang, R., Hou, N., Zhang, Y., & Jia, F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.820544 · Cited by 33
Butt, A. A., Peng, Y., Shaikh, O. S., & Mayr, F. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101117 · Cited by 33
Self-citationMunster, V. J., Flagg, M., Singh, M., Yinda, C. K., Williamson, B. N., Feldmann, F., Pérez-Pérez, L., Schulz, J. E., Brumbaugh, B., Holbrook, M. G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj3627 · Cited by 34
Immune response against SARS-CoV-2 variants: the role of neutralization assays
Chmielewska, A., Czarnota, A., Bieńkowska-Szewczyk, K., & Grzyb, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00404-6 · Cited by 34
Pajón, R., Paila, Y. D., Girard, B., Dixon, G., Kacena, K. A., Baden, L. R., Sahly, H. M. E., Essink, B. J., Mullane, K. M., Frank, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01679-5 · Cited by 35
Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants
Fleming-Dutra, K. E., Zauche, L. H., Roper, L. E., Ellington, S., Olson, C. K., Sharma, A. J., Woodworth, K. R., Tepper, N. K., Havers, F. P., Oliver, S. E., et al. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2023.02.003 · Cited by 35
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Mambelli, F., de Araujo, A. C. V. S. C., Farias, J. P., de Andrade, K. Q., Ferreira, L. C. D. S., Minoprio, P. M. C., Leite, L. C. C., & Oliveira, S. C. (2025) · Pathogens · doi:10.3390/pathogens14010023 · Cited by 32
The Spike of SARS-CoV-2: Uniqueness and Applications
Kumavath, R., Barh, D., Andrade, B. S., Imchen, M., Aburjaile, F. F., Ch, A., Rodrigues, D. L. N., Tiwari, S., Alzahrani, K. J., Goés‐Neto, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663912 · Cited by 34
Chadha, J., Khullar, L., & Mittal, N. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15687 · Cited by 33
Büsching, G., Zhang, Z., Schmid, J., Sigrist, T., & Khatami, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18178956 · Cited by 32
Stirrup, O., Boshier, F. A. T., Venturini, C., Guerra‐Assunção, J. A., Alcolea-Medina, A., Beckett, A. H., Charalampous, T., Filipe, A. D. S., Glaysher, S., Khan, T., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001029 · Cited by 32
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
Dalvie, N. C., Tostanoski, L. H., Rodriguez‐Aponte, S. A., Kaur, K., Bajoria, S., Kumru, O. S., Martinot, A. J., Chandrashekar, A., McMahan, K., Mercado, N. B., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl6015 · Cited by 32
Mirahmadizadeh, A., Heiran, A., Lankarani, K. B., Serati, M., Habibi, M., Eilami, O., Heiran, F., & Moghadami, M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac177 · Cited by 32
Hassen, H. D., Welde, M., & Menebo, M. M. (2022) · BMC Public Health · doi:10.1186/s12889-022-13485-2 · Cited by 34
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
Wang, Q., Anang, S., Iketani, S., Guo, Y., Liu, L., Katsamba, P. S., Shapiro, L. S., Ho, D. D., & Sodroski, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110924 · Cited by 34
Semenzato, L., Botton, J., Drouin, J., Baricault, B., Bertrand, M., Jabagi, M.-J., Cuenot, F., Vu, S. L., Dray‐Spira, R., Weill, A., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100441 · Cited by 36
Nickel, O., Rockstroh, A., Wolf, J., Landgraf, S., Kalbitz, S., Kellner, N., Borte, M., Pietsch, C., Fertey, J., Lübbert, C., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263861 · Cited by 32
Qassim, S. H., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102102 · Cited by 32
Self-citationBouillon, K., Baricault, B., Botton, J., Jabagi, M.-J., Bertrand, M., Semenzato, L., Le Vu, S., Drouin, J., Dray-Spira, R., Weill, A., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000104 · Cited by 31
Mrak, D., Simader, E., Sieghart, D., Mandl, P., Radner, H., Perkmann, T., Haslacher, H., Mayer, M., Koblischke, M., Hofer, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222579 · Cited by 32
SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines
Li, X., Mi, Z., Liu, Z., & Rong, P. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1334152 · Cited by 34
Jantarabenjakul, W., Chantasrisawad, N., Puthanakit, T., Wacharapluesadee, S., Hirankarn, N., Ruenjaiman, V., Paitoonpong, L., Suwanpimolkul, G., Torvorapanit, P., Pradit, R., et al. (2021) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-250721-1197 · Cited by 31
COVID-19 reinfection: the role of natural immunity, vaccines, and variants
Sciscent, B. Y., Eisele, C. D., Ho, L., King, S., Jain, R., & Golamari, R. R. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1974665 · Cited by 31
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Yuan, Y., Zhang, X., Chen, R., Li, Y., Wu, B., Li, R., Zou, F., Ma, X., Wang, X., Chen, Q., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110256 · Cited by 31
Butt, A. A., Peng, Y., Shaikh, O. S., Mayr, F., & Omer, S. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1023 · Cited by 31
Self-citationAttitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland
Babicki, M., & Mastalerz–Migas, A. (2022) · Vaccines · doi:10.3390/vaccines10010068 · Cited by 31
Chen, R., Zhang, X., Yuan, Y., Deng, X., Wu, B., Xi, Z., Wang, G., Lin, Y., Li, R., Wang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202105378 · Cited by 31
Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31
Hospitalization Outcomes Among Patients With COVID-19 Undergoing Remote Monitoring
Crotty, B. H., Dong, Y., Laud, P. W., Hanson, R. J., Gershkowitz, B. D., Penlesky, A. C., Shah, N., Anderes, M., Green, E., Fickel, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.21050 · Cited by 31
Carazo, S., Talbot, D. C., Boulianne, N., Brisson, M., Gilca, R., Deceuninck, G., Brousseau, N., Drolet, M., Ouakki, M., Sauvageau, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab739 · Cited by 32
Malcangi, G., Inchingolo, A. D., Inchingolo, A. M., Santacroce, L., Marinelli, G., Mancini, A., Vimercati, L., Maggiore, M. E., D’Oria, M. T., Hazballa, D., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091964 · Cited by 31
COVID-19 Case Fatality and Alzheimer’s Disease
Zhang, Q., Schultz, J. L., Aldridge, G. M., Simmering, J. E., Kim, Y., Ogilvie, A. C., & Narayanan, N. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215161 · Cited by 30
Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA
Ahn, M., Song, J., & Hong, B. H. (2021) · Nanomaterials · doi:10.3390/nano11112816 · Cited by 30
Singer, S. R., Angulo, F. J., Swerdlow, D. L., McLaughlin, J. M., Hazan, I., Ginish, N., Anis, E., Mendelson, E., Mor, O., Zuckerman, N. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101190 · Cited by 31
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-08
- Volume
- 385
- Issue
- 2
- Pages
- 187-189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117967
- OpenAlex
- W3157162195
- Cited by
- 899
- References
- 4
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 46 · 2023: 92 · 2022: 358 · 2021: 351
- FWCI
- 67.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, the Ministry of Public Health and Hamad Medical Corporation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant, Omicron variant, vaccination campaigns, viral genome sequencing, COVID-19 waves
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Qatar, Cohort Studies, Case-Control Studies, Polymerase Chain Reaction, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
